MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

57.89 -0.30 (-0.52%)
Streaming Delayed Price Updated: 11:17 AM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
News headline image
7 No-Brainer Biotech Stocks to Add to Your Buy List ↗
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. 
Via InvestorPlace
News headline image
7 Oversold Stocks to Buy Right Now ↗
Identifying oversold stocks gives investors the opportunity to buy shares that they perhaps already liked, only at a discounted price. 
Via InvestorPlace
News headline image
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
IBD Tech Leader Vertex Snags Upgrade As Non-Cystic Fibrosis Drugs Crystallize ↗
One analyst expects multiple new drug launches between 2024-26. 
Via Investor's Business Daily
News headline image
Cathie Wood Provides Lesson of the Day: Don't Invest in Fairytale Stocks ↗
Tesla is no longer the No.1 holding of Cathie Wood's ARK. Let's see what's inside. 
Via Talk Markets
Why Orphan Drug Designation Offers Several Benefits
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we... 
Via FinancialNewsMedia
News headline image
Analyst Ratings for CRISPR Therapeutics ↗
Over the past 3 months, 11 analysts have published their opinion on CRISPR Therapeutics (NASDAQ:CRSP) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
How to Buy Stocks in a Recession ↗
The same strategies for buying stocks during a bull market don't apply during a recession. Learn what you need to do going forward. 
Via InvestorPlace
News headline image
5 Cathie Wood Stocks to Buy Now ↗
ARK Invest funds led by Cathie Wood seek long-term capital growth and focus mainly on disruptive innovation. Here's a look a five related stocks to consider. 
Via InvestorPlace
News headline image
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis ↗
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped. 
Via Investor's Business Daily
News headline image
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data ↗
 
Via Benzinga
News headline image
$100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much ↗
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.5% on an annualized basis producing an average annual return of 25.08%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About CRISPR Therapeutics ↗
Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings: 
Via Benzinga
News headline image
3 Cathie Wood Stocks to Count on in Q2 ↗
These Cathie Wood Stocks have their risks but offer a massive upside potential ahead, especially if you can handle the volatility. 
Via InvestorPlace
News headline image
7 Potential Biotech Stocks Buyout Targets in 2022 ↗
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company. 
Via InvestorPlace
News headline image
$1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much ↗
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.85% on an annualized basis producing an average annual return of 28.2%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
News headline image
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 26.02%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
News headline image
3 Best Stocks to Trade Right Now ↗
Get past the persistently bearish headlines, and you'll find stocks to trade long in emerging bull markets that could be lucrative. 
Via InvestorPlace
News headline image
Fed Rate Hike Rallies Stocks ↗
The Federal Reserve led by Jerome Powell hiked interest rates for the first time in three years causing stocks to rally. 
Via Talk Markets
News headline image
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.95% on an annualized basis. Buying $1,000 In CRSP: 5 years ago, an investor could have... 
Via Benzinga
News headline image
3 Ark Invest Most-Shorted Stocks to Buy ↗
These most-shorted stocks have investors seeing red, but there is a silver lining that's playing out on the price chart for today's buyers. 
Via InvestorPlace
News headline image
7 Cathie Wood Stocks That Are Worth Buying in March ↗
Many Cathie Wood stocks have suffered losses over the past year, but these companies will likely see strong gains in the coming quarters. 
Via InvestorPlace
News headline image
3 Cathie Wood Stocks to Buy ↗
Don't buy Cathie Wood stocks because the market was singing on Wednesday, purchase them because of a much bigger and bullish picture. 
Via InvestorPlace
News headline image
Tough Slogging Ahead for Investors, Diversification is Important ↗
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows. 
Via Talk Markets
News headline image
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test ↗
Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein. 
Via Investor's Business Daily
News headline image
Peloton Isn’t the ONLY Takeover Target. What Companies Could Be Bought Out in 2022? ↗
Savvy investors can generate lucrative returns by investing in companies that look like a number of prime takeover targets. 
Via InvestorPlace
News headline image
Why Jim Cramer Believes Sirius XM Is Inexpensive ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said CRISPR Therapeutics AG (NASDAQ: 
Via Benzinga
News headline image
What Are Whales Doing With CRISPR Therapeutics ↗
A whale with a lot of money to spend has taken a noticeably bullish stance on CRISPR Therapeutics. Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 15 strange trades. 
Via Benzinga
News headline image
CRISPR Therapeutics's Return On Capital Employed Insights ↗
Benzinga Pro data, CRISPR Therapeutics (NASDAQ:CRSP) reported Q4 sales of $12.90 million. Earnings fell to a loss of $141.25 million, resulting in a 11.09% decrease from last quarter. 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story